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Summary
Ubiquitin is highly conserved across eukaryotes and is essential for normal 
eukaryotic cell function. The bacterium Bacteroides fragilis is a member 
of the normal human gut microbiota, and the only bacterium known to 
encode a homologue of eukaryotic ubiquitin. The B. fragilis gene sequence 
indicates a past horizontal gene transfer event from a eukaryotic source. 
It encodes a protein (BfUbb) with 63% identity to human ubiquitin which 
is exported from the bacterial cell. The aim of this study was (i) to de-
termine if there was antigenic cross-reactivity between B. fragilis ubiquitin 
and human ubiquitin and (ii) to determine if humans produced antibodies 
to BfUbb. Molecular model comparisons of BfUbb and human ubiquitin 
predicted a high level (99·8% confidence) of structural similarity. Linear 
epitope mapping identified epitopes in BfUbb and human ubiquitin that 
cross-react. BfUbb also has epitope(s) that do not cross-react with human 
ubiquitin. The reaction of human serum (n  =  474) to BfUbb and human 
ubiquitin from the following four groups of subjects was compared by 
enzyme-linked immunosorbent assay (ELISA): (1) newly autoantibody-
positive patients, (2) allergen-specific immunoglobulin (Ig)E-negative pa-
tients, (3) ulcerative colitis patients and (4) healthy volunteers. We show 
that the immune system of some individuals has been exposed to BfUbb 
which has resulted in the generation of IgG antibodies. Serum from pa-
tients referred for first-time testing to an immunology laboratory for 
autoimmune disease are more likely to have a high level of antibodies to 
BfUbb than healthy volunteers. Molecular mimicry of human ubiquitin 
by BfUbb could be a trigger for autoimmune disease.
Keywords: autoimmune disease, Bacteroides fragilis, Coeliac, microbiome, 
multiple sclerosis, rheumatoid arthritis, ubiquitin, ulcerative colitis
Introduction
The resident microbiota of the human gastrointestinal (GI) 
tract is comprised of ~1500 species, with the predominant 
phyla being the Bacteroidetes and the Firmicutes. The 
Gram-negative strictly anaerobic Bacteroides genus domi-
nates, as evidenced by its prevalence in faeces. B. fragilis, 
which is well known as an opportunistic pathogen [1], 
plays an important role in immune cell balancing in the 
GI tract. Some B. fragilis strains produce a capsular 
polysaccharide (PSA) that stimulates dendritic cells to alter 
the ratio of T helper cells and produce interleukin (IL)-10, 
which reduces production of the proinflammatory cytokine 
IL-17 [2]. There is evidence that B. fragilis may not only 
be associated intimately with the colonic mucosa, but also 
may be present intracellularly [3].
During our annotation of the genome sequence of B. 
fragilis we discovered a gene (ubb) encoding a protein 
designated BfUbb, with 63% identity to human ubiquitin 
(e.g. ubc52), located within an 11 kb region of DNA 
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with a lower GC content than the rest of the genome 
[4]. The closest nucleotide homology for ubb [216 base 
pairs (bp)] is with the ubiquitin gene of a Migratory 
Grasshopper Entomopoxvirus (103 of 122 bp), which sup-
ports the notion of interkingdom horizontal gene transfer 
from a eukaryotic source [5]. Ubiquitin is a highly con-
served protein which, until this discovery, has been found 
only in eukaryotes and eukaryotic viruses [6,7]. The protein 
sequence is conserved among mammals. Ubiquitin tagging 
(ubiquitylation) of proteins governs nearly every eukaryotic 
cell function, from intracellular proteolysis, membrane–
protein endocytosis and intracellular trafficking and chro-
matin-mediated regulation of transcription to DNA repair. 
Ubiquitin is also a major factor involved in development 
and function of the immune system. To date, B. fragilis 
is unique in being the only bacterium to encode an iden-
tified ubiquitin homologue. The gene has evolved at least 
two novel features that differentiate the encoded protein 
from eukaryotic ubiquitin: first, B. fragilis ubiquitin (BfUbb) 
contains a signal sequence that directs it to the periplasm, 
and we have found it associated with outer membrane 
vesicles (OMV) [8]; secondly, BfUbb has lost the C-terminal 
glycine residues required for thioester bond formation 
with the catalytic cysteine residue in the eukaryotic E1 
activating enzyme. In place of the glycine residues, there 
is a cysteine that may allow disulphide bond formation 
with the catalytic residues of E1-activating and 
E2-conjugating enzymes of the ubiquitylation pathway. 
Consistent with this, we have shown that BfUbb can bind 
covalently to human E1 under non-reducing conditions 
in vitro and can inhibit ubiquitylation if added to a reac-
tion before eukaryotic ubiquitin [4].
Given the intimate association of B. fragilis with the 
human GI tract and the release of ubiquitin from 
B. fragilis in OMV, we hypothesized that an immune 
reaction to BfUbb might be detectable in humans and, 
potentially, be related to autoimmune disease due to 
molecular mimicry. Here we show that BfUbb and human 
ubiquitin (Hubb) are predicted to be structurally highly 
similar, and we demonstrate that this can be related to 
cross-reactive epitopes. We demonstrate that BfUbb also 
has unique epitope(s). We investigated the reactivity of 
human serum samples related to various conditions, includ-
ing systemic lupus erythematosus (SLE), ulcerative colitis, 
rheumatoid arthritis, coeliac disease and multiple sclerosis, 
in a pilot study. We now report that BfUbb can generate 
an immunoglobulin (Ig)G response in humans and that 
patients referred for autoimmune disease testing are more 
likely to have high levels of IgG reactive with BfUbb 
than healthy volunteers.
Methods
Protein structural comparison and epitope mapping
Anti-BfUbb polyclonal antiserum was produced by inocu-
lation of a New Zealand White rabbit with recombinant 
(r)BfUbb conjugated to keyhole limpet haemocyanin carrier 
protein under UK Government Home Office Personal and 
Project Licences and with local ethical approval, as 
described previously [4]. Serum from a pre-immune bleed 
was reserved as a control. Recombinant human ubiquitin 
(Hubb; >  95% purity) and rabbit polyclonal anti-Hubb 
antiserum were obtained from BostonBiochem (Cambridge, 
MA, USA). Peptides 1,2 and 3 (>  80% purity) and syn-
thetic (s)BfUbb (>  90% purity) were custom synthesized 
by Genosphere Biotechnologies (Paris, France). Structural 
protein comparisons were carried out using the Protein 
Homology/Analogy Recognition Engine (Phyre) 2 web 
portal for protein modelling, prediction and analysis [9] 
and molecular graphics generated using the University 
of California San Francisco (UCSF) Chimera package. 
Chimera is developed by the Resource for Biocomputing, 
Visualization and Informatics at the University of 
California, San Francisco, supported by NIGMS 
P41-GM103311 [10]. Linear epitope mapping was carried 
out by PepScan Presto BV (Lelystad, the Netherlands) 
on linear arrays of overlapping 15-mer and 24-mer pep-
tides generated from the BfUbb and human ubiquitin 
sequences as well as two chimaeric sequences generated 
by swapping alternating divergent amino acids from the 
BfUbb and Hubb sequences. Peptide-scanning enzyme-
linked immunosorbent assays (ELISAs) were carried out 
with the rabbit anti-BfUbb and rabbit anti-Hubb polyclonal 
antisera detailed above and substrate colour development 
was quantified with a charge-coupled device camera with 
values recorded in the range of 0 to 3000 mAU [11,12].
ELISA
Standard ELISAs were carried out in 96-well Nunc MaxiSorp 
microtitre plates which had been coated overnight at 4°C 
with either BfUbb (5  μg ml−1), Hubb (5  μg ml−1) or pep-
tides 1,2 or 3 (10  μg ml−1). Microtitre plates were blocked 
with 1% (w/v) bovine serum albumin (BSA) in phosphate-
buffered saline buffer (PBS; 200  μl) for 2  h. After washing, 
diluted primary antibody (100  μl) was added to triplicate 
wells and incubated shaken for 1·5  h at 37°C. Identical 
primary antibody application microtitre plate templates were 
used for serum samples for the BfUbb and Hubb plates. 
Microtitre plates were drained and washed five times with 
PBS with Tween 20 (0·05% w/v), followed by five  5-min 
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washes; 100  μl of either goat anti-rabbit IgG H&L alkaline 
phosphatase or goat anti-human IgG Fc alkaline phosphatase 
conjugate (Abcam, Cambridge, UK) diluted in 1% (w/v) 
BSA in PBS was added and the plates incubated  shaken 
for 1  h at 37oC. The microtitre plates were drained and 
washed five times with PBS with Tween 20 (0·05% w/v), 
followed by three 5-min washes. p-Nitrophenyl-phosphate 
substrate (50  μl) was added, the plates incubated shaken 
for 1  h at room temperature, the reaction stopped with 
2  M NaOH and the plates read in at 405nm in an ELISA 
reader (Biotek, Winooski, VT, USA). Data for the rabbit 
antiserum BfUbb and Hubb ELISA experiments represent 
the mean of a minimum of two replicate experiments, and 
for the human serum samples data points represent the 
mean of three triplicate wells. Selected human serum titra-
tion experiments were repeated on separate occasions.
Human serum samples
Anonymized serum samples, taken during routine clinical 
practice and surplus to analytical diagnostic requirements, 
were obtained from the Regional Immunology Laboratory, 
Belfast Health and Social Care Trust, Northern Ireland, 
UK and stored at –80°C (Table 1). As the samples were 
unlinked and anonymized, and therefore untraceable, ethi-
cal approval was not a requirement. Serum samples were 
collected during 2016 and 2017 from patients who had 
tested positive for the first time for suspected autoimmune 
diseases, such as systemic lupus erythematosus (SLE) 
(autoimmune antibody category); anti-cyclic citrullinated 
peptide (anti-CCP) antibody-positive (rheumatoid arthritis 
category); anti-tissue transglutaminase (anti-TTG) anti-
body-positive (coeliac category); and oligoclonal banding 
positive on paired cerebrospinal fluid and serum samples 
(multiple sclerosis category). In addition, patient sera which 
had been tested for specific IgE to house dust, animal 
dander or pollen, but had been found to be negative 
(allergy test-negative category), were also collected. 
Anonymous serum samples from patients diagnosed with 
ulcerative colitis were purchased from Sera Laboratories 
International (Haywards Heath, UK). Unlinked 
Table 1. Human serum samples
Sample category Samples (n) Laboratory tests
Average age 
(years) Females n (%)
Coeliac 99 IgA anti-tissue transglu-
taminase and/or
43 60 (61%)
IgA anti-endomysial 
antibodies
Rheumatoid arthritis 83 anti-cyclic citrullinated 
peptide antibodies
54 53 (64%)
Multiple sclerosis 36 IgG oligoclonal band 
detection
46 20 (56%)
Autoimmune antibodies 134 Anti-nuclear antibodies Anti-double-stranded DNA 
antibodies
57 98 (72%)*
Anti-Ro52 and/or Ro60 
antibodies
Anti-La antibodies
Anti-Sm antibodies
Anti-ribonuclear protein 
antibodies
Anti-Scl-70 antibodies
Anti-Centromere protein B 
antibodies
Anti-Chromatin antibodies
Anti-Ribosomal P 
antibodies
3 Anti-cardiolipin and/or
Anti-beta-2-glycoprotein 
antibodies
Allergy test negative 37 Anti-house dust mite, 
animal mix, grass pollen 
mix
50 23 (62%)
Ulcerative colitis 20 Not applicable 46 13 (65%)
Healthy volunteer 61 Not applicable 40 38 (59%)
*one sex unknown
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anonymized serum samples, surplus to requirements from 
healthy volunteers participating in a short-term dietary 
intervention study approved by the Research Ethics 
Committee of the School of Medicine and Dentistry, 
Queen’s University Belfast with written informed consent 
[13], were also obtained.
Statistical analysis
Analysis of the relationship between the proportion of 
human serum samples with an ELISA optical density 
(OD)405  nm reading of >  2·0 or >  2·5 in the serum catego-
ries autoimmune antibodies, coeliac, rheumatoid arthritis, 
multiple sclerosis, allergy test-negative and ulcerative colitis 
versus healthy volunteers was by two-sided Fisher’s exact 
test (P  =  0·05) with IBM spss statistics version 22 (IBM 
Corporation, Armonk, NY, USA).
Results
Molecular modelling and comparison of the immune-
reactivity of BfUbb and human ubiquitin
Comparison of the reactivity of rabbit polyclonal antiserum 
raised against human ubiquitin with recombinant BfUbb 
and human ubiquitin (Hubb) by ELISA revealed similar 
reactivity (Fig. 1a). The reactivity of antiserum raised 
against recombinant BfUbb with Hubb, however, was 
consistently lower than the reaction with recombinant 
BfUbb (Fig. 1b).
These data suggest that BfUbb and Hubb may have 
both shared and unique epitopes.
The amino acid sequence of ubiquitin is highly con-
served in eukaryotes; mammals have identical ubiquitin 
sequences and, for example, Saccharomyces cerevisiae has 
only three amino acid differences. As the BfUbb sequence 
shares 63% identity with the mammalian ubiquitin 
sequence (Fig. 2a), the potential for protein structural 
similarity of BfUbb with mammalian ubiquitin was ana-
lysed using the Phyre 2 web portal for protein modelling, 
prediction and analysis [9]. The analyses revealed the 
potential for structural similarity between BfUbb and Hubb, 
with 99·8% confidence that the sequence match is true 
homology and therefore that the structure is predicted 
correctly (Fig. 2b,c). This is consistent with the hypothesis 
that the two proteins have potentially cross-reactive 
epitopes. There are, however, a number of key amino 
acid differences that may form distinct epitopes. Notably, 
there is a lysine at position 11 in human ubiquitin which 
has been replaced by a tryptophan residue in BfUbb (Fig. 
2a). These residues are surface exposed in the predicted 
structure (Fig. 2b,c). The amino acids at the C-terminus 
diverge (Fig. 2a) and may form unique epitopes. Therefore, 
the immune reactivity of three short synthetic peptides 
(Fig. 2a) from the N-terminal sequence inclusive of the 
tryptophan residue and the divergent C-terminal sequence 
were compared with synthetic whole molecule BfUbb 
(sBfUbb) to determine if these sequences contained con-
served or divergent epitopes (Fig. 3). The pattern of reac-
tivity of the rabbit polyclonal anti-BfUbb and anti-human 
ubiquitin antiserum with the peptides was similar to that 
observed with the whole human ubiquitin and BfUbb 
proteins. Reaction with the anti-human ubiquitin antiserum 
Fig. 1. Comparison of enzyme-linked immunosorbent assay (ELISA) reaction of rabbit polyclonal antiserum with Bacteroides fragilis and human 
ubiquitin. (a) Anti-recombinant human ubiquitin (Hubb) antiserum and (b) anti-recombinant B. fragilis ubiquitin (rBfUbb) antiserum with rBfUbb 
(diamond), synthetic Bacteroides fragilis ubiquitin (sBfUbb; square) and Hubb (triangle). Black, immune serum; blue, preimmune serum. Initial 
dilution 1/500. Mean of two or more replicate experiments ± SD.
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was higher than the reaction with the anti-BfUbb anti-
serum. This suggests that these peptides do not contain 
the immunodominant BfUbb epitopes recognized by the 
anti-BfUbb antiserum.
To further investigate the cross-reactivity and to deter-
mine potential shared epitopes, the reaction of the polyclonal 
antisera with libraries of linear peptides was examined. 
Four series of peptides were synthesized with sequences 
derived from BfUbb, human ubiquitin and two BfUbb/
human ubiquitin chimaeric sequences (Fig. 4a). These were 
tested with the polyclonal antisera using PepScan technol-
ogy [12]. For each of the BfUbb, human ubiquitin and 
the two chimaeric sequences, 61  peptides, each 15  amino 
acids long with an overlap of 14  amino acids, and 52  pep-
tides of 24  amino acids with an overlap of 23  amino acids 
were tested. The BfUbb-derived peptide sequences are 
indicated in the x-axis labels of Fig. 4b,c. Probing of the 
arrays with anti-Hubb antiserum revealed two potential 
shared linear epitopes in the BfUbb and Hubb sequences 
(Fig. 4a–d). The putative BfUbb O- glycosylation sites DTV 
and DST are not within either of these epitopes (Fig. 4d). 
The anti-rBfUbb antiserum did not have a detectable reac-
tion with the shared epitopes identified by the anti-Hubb 
antiserum (Fig. 4b,c). This suggests that there are too few 
antibodies to the shared linear epitopes present in the anti-
rBfUbb antiserum to be detectable in this assay. This is 
in accordance with the lower reaction of the anti-BfUbb 
antiserum to Hubb in the whole molecule titration assay 
(Fig. 1b). It also suggests that the immunodominant BfUbb 
epitopes recognized by the anti-BfUbb antiserum are con-
formational epitopes. At a 1/500 dilution, the anti-rBfUbb 
reacted with the 24-mer GWTITLEVSPTDTVEN 
VKQKIQDK from BfUbb, which suggests a potential unique 
conformational epitope (Fig. 4c, top panel). The position 
of the 24-mer peptide relative to the shared epitopes iden-
tified by the anti-Hubb antiserum is illustrated in the 
Supporting information, Fig. S1.
Human serum reactivity with BfUbb and human 
ubiquitin
On the basis of the differential reactivity of the rabbit 
antisera to BfUbb and Hubb, the IgG ELISA reactivity 
of anonymous human antiserum with either human ubiq-
uitin or sBfUbb whole molecule was examined. Serum 
samples surplus to diagnostic requirements from 393 indi-
viduals who had tested positive for the first time by the 
regional immunology laboratory for a variety of different 
conditions, 20  serum samples from individuals diagnosed 
with ulcerative colitis and 61 serum samples from healthy 
individuals were tested (Table 1). It is clear that some 
individuals have high ELISA OD readings for BfUbb or 
both BfUbb and Hubb (Fig. 5a,b). In contrast, no indi-
viduals had a high OD reading for Hubb and a low OD 
reading for BfUbb. The levels of autoantibodies detected 
in the immunology laboratory tests did not relate directly 
to the level of antibodies to either BfUbb of Hubb, nor 
did the distribution of antinuclear subtypes demonstrate 
any clear pattern of association with antibodies to BfUbb 
or Hubb (Supporting information, Table S1). The data 
indicate clearly, however, that the immune system of some 
individuals with autoimmune disorders has been exposed 
to BfUbb, which has resulted in the generation of IgG 
Fig. 2. Comparison of BfUbb and Hubb structural models. (a) Amino acid sequence alignment of Hubb, BfUbb and synthetic peptide sequences. 
Tryptophan and lysine underlined. Molecular graphic of (b) ribbon model and (c) mesh surface model (i) BfUbb modelled on human ubiquitin (ii) 
Human ubiquitin. Arrow: position of tryptophan 11 in BfUbb and corresponding lysine 11 in human ubiquitin. Rainbow-coloured; N terminus (blue), 
C terminus (red). 
(a)
(b) (c)
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antibodies reactive with BfUbb epitopes not present in 
Hubb.
To determine if there was any significant difference in 
the number of individuals with higher titres of specific 
antibodies in the different human serum categories, the 
proportion of samples with an OD reading above either 
2·0 or 2·5 was determined (Fig. 5c). The difference in 
the proportion of each of the categories was compared 
for statistical significance with the healthy volunteer sam-
ples (P  =  0·05). The greatest proportion of patients with 
high levels of IgG reactive with BfUbb was in the category 
which included 134 samples positive for anti-nuclear anti-
bodies and three patients with anti-cardiolipin and 
anti-beta-2-glycoprotein antibodies, with 37% (46 of 137) 
of samples having an OD >  2·0 and 24% (33 of 137) 
and OD >  2·5. The proportion reactive with Hubb, how-
ever, was not significantly different to the healthy volunteers 
(Fig. 5c). This indicates that individuals who had been 
referred for immunology laboratory testing for suspected 
autoimmune disease were statistically more likely to have 
high levels of BfUbb-reactive antibodies than healthy indi-
viduals. Included within this group were two individuals 
with antibodies to beta-2-glycoprotein and cardiolipin.
The proportion of individuals in the categories rheu-
matoid arthritis, multiple sclerosis, coeliac, ulcerative colitis 
and allergy test-negative were statistically significantly higher 
(P = 0.05) than the healthy volunteer group at an OD > 2·0, 
but not an OD  >  2·5. Of the individuals referred for 
testing for anti-cyclic citrullinated peptide antibodies, 19% 
(16 of 83) had an OD  >  2 of anti-BfUbb antibodies and 
13% (11 of 83) an OD  >  2·5. Individuals referred for 
testing for suspected multiple sclerosis, with a positive test 
for oligoclonal band detection, were least likely to have a 
high reaction to either BfUbb or Hubb; indeed, only one 
of 36 had an OD  >  2·5 and none of the serum samples 
from these individuals reached saturation OD (>  4·1) in 
the ELISA test. Similarly, none of the ulcerative colitis 
samples reached saturation and one of 20 had an OD > 2·5. 
Interestingly, three of the individuals who had been referred 
for allergy to dust mites, mixed pollen and mixed animal 
antigens, but in whom specific IgE had not been detected 
(n  =  37), had OD  >  3·0 for both BfUbb and Hubb. The 
pattern of reaction with individuals who tested positive 
for IgA anti-tissue transglutaminase antibodies, indicative 
of coeliac disease, differed from the other categories. The 
proportion of individuals with both anti-BfUbb and Hubb 
IgG OD  >  2·0 and OD  >  2·5 was significantly higher 
(P  <  0·006) than the healthy volunteers.
Selected serum samples from each category were titrated 
by doubling dilution and tested for reactivity with BfUbb 
and Hubb. Examples of the titration patterns are illustrated 
in Fig. 6a–d: (a) and (b) illustrate a dominant reaction 
to BfUbb unique epitopes, (c) illustrates reaction to cross-
reactive epitopes and (d) a lack of reactivity. Individuals 
with the same positive immunology test result could have 
different titration patterns, as illustrated in Fig. 6b–d serum 
samples, which were from three different anti-ribosomal 
P protein-positive individuals. Further example titrations 
are presented in  Supporting information, Fig. S2 to illus-
trate that both an immunodominant reaction to BfUbb 
and cross-reaction patterns were present in different serum 
sample categories. Some samples had an OD  >  2 at dilu-
tions greater than 1/400.
The reaction to the 12-mer BfUbb N terminal peptide 
1 was also examined in a selection of serum samples. 
Figure 7a is a human serum sample with an immuno-
dominant reaction to BfUbb, while Fig. 7b illustrates 
reaction to cross-reactive epitopes. As with the rabbit 
Fig. 3. Comparison of enzyme-linked immunosorbent assay (ELISA) reaction of rabbit polyclonal antiserum with BfUbb and synthetic peptides. 
(a) Anti-recombinant human ubiquitin (Hubb) antiserum and (b) anti-recombinant B. fragilis ubiquitin (rBfUbb) antiserum with: synthetic Bacteroides 
fragilis ubiquitin (sBfUbb, square); peptide 1- QVFIKNRYGWTI (cross); peptide 2- QVFIKNRYGWTITL (circle); peptide 3- DSTILICIRDVDC (x). 
Black, immune serum; blue, preimmune serum. Initial dilution 1/100.
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polyclonal antiserum (Fig. 3), a similar reaction with 
human ubiquitin and peptide 1 was observed (Fig. 7 and 
Supporting information, Fig. S3). This indicates that the 
N- terminal linear peptide contains an epitope which can 
also be cross-reactive in humans.
Discussion
It is evident that BfUbb and Hubb have potentially highly 
similar molecular structures which are sufficient to result 
in cross-reacting epitopes. Our data clearly demonstrate 
an immune response to BfUbb in human serum samples; 
some individuals have higher titre antiserum reactive with 
BfUbb when compared with human ubiquitin. This indi-
cates that both unique BfUbb epitopes and epitopes shared 
with Hubb can be recognized. The reaction of the human 
serum samples to the BfUbb peptide 1 provides clear 
evidence that there is the potential for antibodies to both 
BfUbb and Hubb within human serum (Fig. 7). Patients 
referred for first-time serum testing to the regional immu-
nology laboratory for a variety of different conditions are 
more likely to have antibodies to BfUbb than healthy 
volunteers, which suggests a potential relationship with 
human disease. It is interesting that the multiple sclerosis 
and ulcerative colitis patients did not exhibit the high 
levels of antibodies observed in the other autoimmune 
conditions; this may be related to differences in the immu-
nological pathogenesis and dominant hypersensitivity 
mechanisms in these different disorders. Muller and col-
leagues [14] reported that 79% of 161 patients with sys-
temic lupus erythematosus (SLE) had antibodies reactive 
with human ubiquitin and a synthetic peptide composed 
of residues 22–45. One of the two Hubb-BfUbb cross-
reactive epitopes that we identified is within this 22–45 
residue region. Muller and colleagues also detected ubiq-
uitin-specific antibodies in 16% of rheumatoid arthritis 
and 15% of scleroderma patients. These authors studied 
successive serum samples from seven patients during active 
and inactive SLE phases and reported that anti-ubiquitin 
antibodies were detected before anti-DNA antibodies and 
observed a reaction with ubiquitin–histone complexes. 
Our observed titration pattern for BfUbb and Hubb may 
also represent different stages in antibody production with 
an initial reaction where unique BfUbb epitopes predomi-
nate (Fig. 6a), followed by a progression towards, and 
concomitant increase in, antibodies to BfUbb/Hubb cross-
reactive epitopes. The titration pattern in Fig. 6b could 
represent an early stage of this progression.
Molecular mimicry by infectious agents is hypothesized 
to be a trigger for the development of autoimmunity. It 
is proposed that exposure of the immune system to exog-
enous molecules with a sufficiently similar structure either 
breaks tolerance to self-antigens or activates pre-existing 
but unreactive immune system cells [15,16]. Viral and bac-
terial molecules from pathogens have been associated with 
triggering autoimmune diseases, but conclusive proof of a 
direct relationship has remained elusive in many instances 
[17]. More recently, bacterial population shifts in the intes-
tinal microbiota from a state of symbiosis to dysbiosis have 
been linked to many conditions, including autoimmune 
disease. For example, animal models implicate bacteria in 
the triggering of rheumatoid arthritis (e.g. [18]). The mecha-
nistic details of the microbiota associations, however, cannot 
be determined by metagenomics or metataxonomics alone, 
as such studies only imply correlations.
Clearly, as B. fragilis are members of the GI tract 
microbiota, conditions, diseases or infections that impact 
upon the integrity of the gut epithelium will be important 
in the exposure of the immune system to ubiquitin. Some 
isolates of B. fragilis produce a zinc-dependent metallo-
protease enterotoxin (BFT) that has been associated with 
childhood diarrhoea, colonic inflammation and potentially 
colon cancer [1]. The enterotoxin increases colonic epi-
thelial permeability by inducing changes to and dissolution 
of the epithelial tight junctions, thought to be caused by 
BFT cleavage of the zonula adherens protein E-cadherin. 
Carriage of BFT-positive B. fragilis is not always associ-
ated with acute diarrhoeal disease, as enterotoxigenic 
B. fragilis can be isolated from healthy individuals [1]. 
The reasons for this are unknown, but the BFT protein 
Fig. 4. Reaction of rabbit polyclonal anti-BfUbb and anti-Hubb antiserum with linear peptide libraries derived from BfUbb and Hubb sequences. 
(a) Bacteroides fragilis (BfUbb), human (Hubb) ubiquitin amino acid sequences and BfUbb/Hubb chimaeric sequences used to generate the 15-mer and 
24-mer PepScan linear peptide libraries. Sequence identity, grey shading; linear epitopes recognised by the anti-rHubb antiserum, red and green. 
(b) Plots of enzyme-linked immunosorbent assay (ELISA) results for 15-mer PepScan linear peptide arrays probed with anti-rBfUbb (top) and anti-
rHubb (bottom) 1/2000 dilution rabbit polyclonal anti-sera. The BfUbb peptide sequences are indicated in the x-axis labels; the equivalent Hubb and 
chimaeric peptide sequences can be derived from the alignments in (a). (c) Plots of ELISA results for 24-mer PepScan linear peptide arrays probed with 
anti-rBfUbb (top: 1/500 dilution; middle: 1/2000 dilution) and anti-rHubb (bottom: 1/2000 dilution) rabbit polyclonal antisera. The BfUbb peptide 
sequences are indicated in the x-axis labels; the equivalent Hubb and chimaeric peptide sequences can be derived from the alignments in (a). Bars 
indicate regions containing linear epitopes recognized by the anti-rHubb antiserum (d). Molecular graphic of BfUbb (left) and Hubb (right) ribbon 
models; shared linear epitopes (red and green) showing mesh surface model. Putative BfUbb glycosylation sites, purple. Arrow: position of tryptophan 
11 in BfUbb and corresponding lysine 11 in human ubiquitin.
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Fig. 5. Comparison of immunoglobulin (Ig)G reaction of human serum samples with sBfUbb and Hubb by enzyme-linked immunosorbent assay 
(ELISA). (a) Plot of optical density (OD) readings for BfUbb versus Hubb (1/90 serum dilution). Category: autoimmune antibodies (ANA), diamond; 
rheumatoid arthritis (RA), open circle; multiple sclerosis (MS), x; ulcerative colitis (UC), triangle; coeliac, open square; allergy test negative (allergy–
ve), solid circle; healthy volunteer (HV), solid square. (b) Plot of OD reading versus serum category (1/90 serum dilution) for reaction with sBfUbb 
(grey) and Hubb (black). Bar = mean OD reading. (C) Percentage within sample category (1/90 serum dilution) with an OD > 2 (solid fill) and OD > 2·5 
(diagonal stripes); sBfUbb (grey), Hubb (black). *Indicates statistically significant difference with the healthy volunteer samples by Fisher’s exact test 
(two-sided). 
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can undergo spontaneous autodigestion. The BFT gene 
is located within a potentially mobile genetic element of 
approximately 6-kbp in size with 12  bp direct repeats at 
either end [1]. This BFT element is variably present in 
large genomic islands, including integrative and conjuga-
tive genetic elements, that are transferred horizontally 
within the B. fragilis pan-genome [19]. There is the potential 
for more than one copy of the BFT gene to be present 
at different chromosomal locations. The carriage of BFT 
genes and therefore ability to produce the enterotoxin is 
highly variable among B. fragilis strains. The variable 
exposure of individuals to BfUbb, and therefore the vari-
able development of anti-BfUbb antibodies, could be 
dependent upon colonization by B. fragilis carrying both 
the BfUbb gene and the BFT gene. GI tract infections 
caused by other organisms that affect GI tract permeability 
could impact equally upon BfUbb exposure.
In addition, B. fragilis has a highly complex and dynamic 
interaction with the immune system due to the ON–
OFF–ON variable production of at least 11 molecularly 
and antigenically different polysaccharides within an indi-
vidual strain. B. fragilis contains a great diversity in capsule 
biosynthesis with multiple polysaccharide biosynthesis 
operons within the pan-genome; for example, a total of 
28 different polysaccharide biosynthesis operons were 
identified in the first three genomes sequenced [19,20]. 
One of these variably produced polysaccharides, PSA, has 
been reported to influence regulatory T cell (Treg) devel-
opment, but PSA is variably produced within a B. fragilis 
population [21]. In addition, not all B. fragilis strains 
carry the PSA biosynthesis operon. These variable poly-
saccharides coat the bacterial cell surface and the OMV 
[8] with which BfUbb is also associated [4].
Factors which influence the potential delivery of BfUbb 
to immune system cells and subsequent immune system 
events could therefore include the damage of GI tract 
epithelium by B. fragilis enterotoxin or other GI tract 
pathogens and the types of B. fragilis polysaccharides being 
produced within the population and present on OMVs. 
Activation of Tregs by interleukin (IL-10) is dependent upon 
the engulfment of B. fragilis OMV by dendritic cells [2]. 
While the evolution of this commensal relationship has 
provided cues for immune regulation, it also provides the 
opportunity for presentation of potential antigens that 
mimic host molecules. Although BfUbb appears to func-
tion as a competitive inhibitor of other B. fragilis strains 
in the gut [22], our data show that the similarity to 
eukaryotic ubiquitin can lead to the generation of anti-
bodies against self-epitopes. This might go beyond proteins 
and include other molecules such as cardiolipin, which 
is present in the outer membranes of many Gram-negative 
bacteria [23], including B. fragilis. Interestingly, one of 
the human serum samples with a high titre reaction to 
BfUbb also had anti-cardiolipin antibodies (Fig. 6a).
A loss of epithelial integrity may precede gluten sen-
sitivity in individuals with a genetic predisposition to 
coeliac disease [24]. Interestingly, there is an increased 
risk of coeliac disease development with multiple gastro-
intestinal infections [25]. The high incidence of anti-BfUbb 
and anti-Hubb antibodies in the coeliac serum category 
could therefore reflect early exposure to BfUbb and could 
be an additional aetiological factor for coeliac disease 
development. Repeated GI infections leading to BfUbb 
exposure could also be a factor in individuals with genetic 
predispositions to other diseases.
Extracellular ubiquitin is detectable in serum at nanogram 
ml−1 concentrations [26] in healthy individuals. Slightly 
elevated nanogram ml−1 concentrations have been associated 
with a number of diseases. Examples include liver cirrhosis, 
type 2 diabetes, sepsis, leukaemia, rheumatoid arthritis, 
Fig. 7. Example titrations of the immunoglobulin (Ig)G reactivity of human serum samples; comparison of whole molecule BfUbb (square), Hubb 
(triangle) and peptide 1-QVFIKNRYGWTI (cross). Initial dilution 1/100. Immunology laboratory test positive for (a) anti-cardiolipin antibody and 
(b) anti-tissue transglutaminase and endomysial antibody [standard deviation (s.d.)].
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allergy to Hymenoptera venom, schistosomiasis, acute viral 
hepatitis and patients undergoing haemodialysis. While a 
major source of extracellular ubiquitin is likely to be cell 
lysis, there is also evidence of active cellular secretion of 
ubiquitin. Extracellular ubiquitin may play a role in immune 
system regulation [27]. It has also been proposed that extra-
cellular ubiquitin masks cell debris, thus preventing an 
autoimmune response to the debris molecules [28]. Clearly 
anti-ubiquitin antibodies may play a role in systemic auto-
immune rheumatic diseases, as well as other conditions.
Extracellular ubiquitin–proteasome interaction in mam-
mals and other animals is necessary for sperm–egg penetra-
tion and therefore essential for successful fertilization [29]. 
Concentrations of ubiquitin in human seminal plasma of 
between 1·8 and 19·1  μg ml−1 have been reported [30]. A 
monoclonal antibody specific for polyubiquitin was shown 
to inhibit fertilization in an Ascidian model system [31], 
and it is recognized that inhibition of extracellular ubiq-
uitin–proteasome activity results in infertility in mammals 
[29]. In addition, anti-sperm antibodies can cause infertility 
in both men and women [32]. High levels of anti-ubiquitin 
antibodies could therefore potentially impact on fertility.
As our data were generated from a pilot study of 
anonymous serum samples, the clinical details of the 
patients are unknown. Therefore, these individuals may 
have had conditions or symptoms not related to the tests 
for which they had been referred. The consequences of 
circulating serum antibodies predominantly reactive with 
only BfUbb are currently unknown; however, the levels 
of antibodies to Hubb detected in our study could clearly 
be highly significant for health.
In conclusion, we have shown that the homologue of 
human ubiquitin BfUbb, produced uniquely by Bacteroides 
fragilis, a normal resident bacterium in the human gut, 
can generate IgG antibodies in humans. We also demon-
strate that the close sequence and structural similarity of 
BfUbb and human ubiquitin results in cross-reactive 
epitopes. Antibodies to ubiquitin may potentially have 
multiple impacts on human health, depending on co-
morbidities. The timing and route of exposure to BfUbb 
could be critical in disease processes. It will therefore be 
important to determine if an immune reaction to BfUbb 
is a consequence and/or a driver of disease. Resolving 
this conundrum could identify entirely novel disease pat-
terns. It could also significantly improve our current 
understanding of the conditions for which the patients 
in this study were referred for testing.
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Supporting Information
Additional supporting information may be found in the 
online version of this article at the publisher’s web site:
Fig. S1. Molecular graphic of BfUbb shared Hubb epitopes 
and putative BfUbb unique epitope containing region. 
BfUbb ribbon model; linear epitopes shared with Hubb 
(red and green) and putative unique BfUbb epitope 
region (blue) showing (a) solid and (b) mesh surface 
models. The position of the tryptophan 11 residue is 
indicated (arrow).
Fig. S2. Example titrations of the IgG reactivity of human 
serum samples; comparison of Hubb (triangle) and BfUbb 
(square). Immunology Laboratory test positive for: (i) and 
(ii) anti- tissue transglutaminase and endomysial antibody; 
(iii) and (iv) anti-cyclic citrullinated peptide antibody; (v) 
and (vi) allergy test negative; (vii) detection of oligoclonal 
bands; (viii) ulcerative colitis patient sample; (ix) anti-
Scl-70 antibody; (x) anti-La antibody and (xi) anti-Ro52 
and Ro60 antibody. Initial dilution 1/90. In (ii, iv, vi, ix 
and xi) replicate experiments with 1/100 initial dilution 
and a 1/90 dilution single point replicate (BfUbb, star; 
Hubb, X)  are also illustrated. Error bars (SD). 
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Fig. S3. Example titrations of the IgG reactivity of human 
serum samples; comparison of whole molecule BfUbb 
(square), Hubb (triangle) and Peptide 1-QVFIKNRYGWTI 
(cross). Initial dilution 1/100. Immunology Laboratory test 
positive for (i) anti-dsDNA, -chromatin, -Ro 52, -Ro 60 
and –centromere antibody and (ii) anti-cyclic citrullinated 
peptide antibody. Error bars (SD).
Table S1. Comparison of ELISA IgG reaction to BfUbb 
and Hubb with Immunology Laboratory test results 
